

Sten Madsbad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4797501/publications.pdf>

Version: 2024-02-01

305
papers

17,557
citations

15504

65
h-index

17105

122
g-index

319
all docs

319
docs citations

319
times ranked

14983
citing authors

#	ARTICLE	IF	CITATIONS
1	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 77-87.	3.6	6
2	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 212-220.	4.4	4
3	Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. <i>Free Radical Biology and Medicine</i> , 2022, 178, 18-25.	2.9	1
4	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. <i>Pharmacological Research</i> , 2022, 176, 106058.	7.1	13
5	The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment. <i>Obesity Surgery</i> , 2022, 32, 998-1004.	2.1	3
6	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2022, 10, e15157.	1.7	3
7	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2022, 65, 506-517.	6.3	37
8	Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. <i>European Journal of Endocrinology</i> , 2022, 186, 687-700.	3.7	12
9	Long-term outcomes of dietary carbohydrate restriction for HbA1c reduction in type 2 diabetes mellitus are needed. Reply to Kang J and Ma E [letter]. <i>Diabetologia</i> , 2022, , 1.	6.3	0
10	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 75-83.	1.2	7
11	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. <i>Human Reproduction</i> , 2022, 37, 1414-1422.	0.9	34
12	Early effects of Roux-en-Y gastric bypass on dietary fatty acid absorption and metabolism in people with obesity and normal glucose tolerance. <i>International Journal of Obesity</i> , 2022, 46, 1359-1365.	3.4	0
13	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Frontiers in Nutrition</i> , 2022, 9, 889710.	3.7	4
14	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial. <i>Clinical Nutrition</i> , 2022, , .	5.0	5
15	Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. <i>Nature Communications</i> , 2022, 13, .	12.8	14
16	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2017-2026.	4.4	9
17	Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. <i>International Journal of Clinical Practice</i> , 2021, 75, e13731.	1.7	22
18	Impact of prolonged fasting on insulin secretion, insulin action, and hepatic versus whole body insulin secretion disposition indices in healthy young males. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E281-E290.	3.5	13

#	ARTICLE	IF	CITATIONS
19	Effects of carbohydrate restriction on postprandial glucose metabolism, β -cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E7-E18.	3.5	17
20	Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes. International Journal of Obesity, 2021, 45, 316-325.	3.4	3
21	The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e11-e19.	3.6	12
22	What is Diabetes Remission?. Diabetes Therapy, 2021, 12, 641-646.	2.5	6
23	Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes, Obesity and Metabolism, 2021, 23, 1397-1401.	4.4	53
24	Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes. European Journal of Case Reports in Internal Medicine, 2021, 8, 002352.	0.4	0
25	Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2021, 320, G753-G758.	3.4	1
26	Effects of a Self-Prepared Carbohydrate-Reduced High-Protein Diet on Cardiovascular Disease Risk Markers in Patients with Type 2 Diabetes. Nutrients, 2021, 13, 1694.	4.1	6
27	Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity. Journal of the Endocrine Society, 2021, 5, A64-A65.	0.2	4
28	Genetic markers of abdominal obesity and weight loss after gastric bypass surgery. PLoS ONE, 2021, 16, e0252525.	2.5	3
29	Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass. Frontiers in Endocrinology, 2021, 12, 681116.	3.5	7
30	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 2021, 384, 1719-1730.	27.0	171
31	Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet. European Journal of Nutrition, 2021, 60, 4473-4482.	3.9	5
32	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. Surgery for Obesity and Related Diseases, 2021, 17, 1383-1391.	1.2	19
33	Dulaglutide for erectile dysfunction in type 2 diabetes. Lancet Diabetes and Endocrinology, 2021, 9, 472-473.	11.4	1
34	Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	3.0	2
35	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. Journal of Clinical Medicine, 2021, 10, 3783.	2.4	21
36	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 2752-2762.	4.4	16

#	ARTICLE	IF	CITATIONS
37	Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E443-E452.	3.5	5
38	Metabolic improvement after gastric bypass correlates with changes in IGF-regulatory proteins stanniocalcin-2 and IGFBP-4. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154886.	3.4	8
39	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. <i>Bone</i> , 2021, 152, 116065.	2.9	8
40	Fractionated free fatty acids and their relation to diabetes status after Roux-en-Y gastric bypass: A cohort study. <i>Physiological Reports</i> , 2021, 9, e14708.	1.7	1
41	Intestinal sensing and handling of dietary lipids in gastric bypass-operated patients and matched controls. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 28-41.	4.7	7
42	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 117-125.	2.7	7
43	Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 492-500.	4.4	29
44	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1&5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 303-314.	4.4	19
45	Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 150.	6.8	11
46	Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107681.	2.3	1
47	The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. <i>Clinical Nutrition ESPEN</i> , 2020, 39, 46-52.	1.2	8
48	Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma. <i>Physiological Reports</i> , 2020, 8, e14519.	1.7	6
49	59 - Greater Reductions in HbA1c and Body Weight With Once-Weekly Semaglutide Vs Comparators Across Baseline BMI Subgroups: Posthoc Analysis of SUSTAIN 1&5 and 7&10. <i>Canadian Journal of Diabetes</i> , 2020, 44, S25-S26.	0.8	0
50	Mechanisms Underlying Absent Training-Induced Improvement in Insulin Action in Lean, Hyperandrogenic Women With Polycystic Ovary Syndrome. <i>Diabetes</i> , 2020, 69, 2267-2280.	0.6	13
51	Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. <i>Hepatology Communications</i> , 2020, 4, 1610-1623.	4.3	22
52	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. <i>International Journal of Obesity</i> , 2020, 44, 1872-1883.	3.4	13
53	Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 401-407.	1.2	10
54	Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2020, 107, 160-169.	3.1	7

#	ARTICLE	IF	CITATIONS
55	No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1837-1846.	4.4	4
56	Metformin monotherapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD012906.	2.8	21
57	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E956-E964.	3.5	13
58	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 313-324.	11.4	39
59	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. <i>International Journal of Obesity</i> , 2020, 44, 1859-1871.	3.4	25
60	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G661-G672.	3.4	27
61	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism: A Randomized Crossover Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1448-1458.	2.8	17
62	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. <i>Cell Reports Medicine</i> , 2020, 1, 100006.	6.5	22
63	Reduction of oxidative stress on DNA and RNA in obese patients after Roux-en-Y gastric bypass surgery: An observational cohort study of changes in urinary markers. <i>PLoS ONE</i> , 2020, 15, e0243918.	2.5	10
64	Title is missing!. , 2020, 15, e0243918.		0
65	Title is missing!. , 2020, 15, e0243918.		0
66	Title is missing!. , 2020, 15, e0243918.		0
67	Title is missing!. , 2020, 15, e0243918.		0
68	Title is missing!. , 2020, 15, e0243918.		0
69	Title is missing!. , 2020, 15, e0243918.		0
70	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1241-1257.	7.3	47
71	Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. <i>Atherosclerosis</i> , 2019, 288, 60-66.	0.8	43
72	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2019, 62, 2066-2078.	6.3	98

#	ARTICLE	IF	CITATIONS
73	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. <i>Scientific Reports</i> , 2019, 9, 15154.	3.3	6
74	Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study. <i>Lipids in Health and Disease</i> , 2019, 18, 169.	3.0	5
75	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3233-3244.	3.6	15
76	Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 243-257.	2.4	5
77	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 42.	2.7	10
78	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. <i>Bone</i> , 2019, 125, 178-185.	2.9	45
79	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 242.	3.5	5
80	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2509-2519.	3.6	29
81	Genetic Determinants of Weight Loss After Bariatric Surgery. <i>Obesity Surgery</i> , 2019, 29, 2554-2561.	2.1	17
82	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 377-387.	1.5	8
83	Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2012-2016.	4.4	14
84	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. <i>Gastroenterology</i> , 2019, 156, 1627-1641.e1.	1.3	99
85	Bariatric surgery— which procedure is the optimal choice?. <i>Lancet, The</i> , 2019, 393, 1263-1264.	13.7	10
86	Assessment of Islet Alpha- and Beta-Cell Function. , 2019, , 37-74.		1
87	Molecular Mechanisms in Skeletal Muscle Underlying Insulin Resistance in Women Who Are Lean With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1841-1854.	3.6	50
88	The effect of DPP-4-protected GLP-1 (7-36) on coronary microvascular function in obese adults. <i>IJC Heart and Vasculature</i> , 2019, 22, 139-144.	1.1	5
89	Effect of bariatric surgery on plasma GDF15 in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E615-E621.	3.5	25
90	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. <i>BMJ Open</i> , 2019, 9, e031431.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Metabolic Health in Severely Obese Subjects: A Descriptive Study. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 115-119.	1.3	3
92	Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 296-304.	4.7	22
93	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 1-45.	0.1	3
94	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 708-714.	1.2	144
95	A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients. <i>British Journal of Nutrition</i> , 2018, 119, 910-917.	2.3	39
96	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. <i>EBioMedicine</i> , 2018, 28, 234-240.	6.1	5
97	Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. <i>Diabetes Care</i> , 2018, 41, 797-806.	8.6	10
98	Metformin monotherapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2018, , .	2.8	6
99	Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes – A Simulation Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 322-330.	2.5	4
100	Overnight glucose control in people with type 1 diabetes. <i>Biomedical Signal Processing and Control</i> , 2018, 39, 503-512.	5.7	40
101	The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial. <i>Lipids in Health and Disease</i> , 2018, 17, 295.	3.0	9
102	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1429-1432.	1.5	17
103	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. <i>Cell Systems</i> , 2018, 7, 601-612.e3.	6.2	80
104	Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations – Role of Carbohydrate and Energy Availability. <i>Diabetes</i> , 2018, 67, 2129-2136.	0.6	74
105	Preoperative High-Dose Methylprednisolone and Glycemic Control Early After Total Hip and Knee Arthroplasty. <i>Anesthesia and Analgesia</i> , 2018, 127, 906-913.	2.2	15
106	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 571-615.	0.1	1
107	Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects. <i>Nutrients</i> , 2018, 10, 1285.	4.1	12
108	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. <i>Cell Metabolism</i> , 2018, 28, 23-32.e3.	16.2	88

#	ARTICLE	IF	CITATIONS
109	Changes in Serum Sphingomyelin After Roux-en-Y Gastric Bypass Surgery Are Related to Diabetes Status. <i>Frontiers in Endocrinology</i> , 2018, 9, 172.	3.5	10
110	Non-insulin pharmacological therapies for treating type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 947-960.	1.8	25
111	After Roux-en-Y Gastric Bypass, Enterohepatic Bile Circulation Is Altered and Bile Acid Retention Increased while Bile Acid Homeostasis Remains Normal after Sleeve Gastrectomy. <i>Diabetes</i> , 2018, 67, .	0.6	2
112	Liraglutide effects on beta cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 850-857.	4.4	19
113	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017, 389, 1399-1409.	13.7	502
114	Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 1101-1111.	2.2	14
115	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R797-R805.	1.8	15
116	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E284-E291.	3.5	13
117	Glycaemic control and weight loss with semaglutide in type 2 diabetes. <i>Lancet Diabetes and Endocrinology, the</i> , 2017, 5, 315-317.	11.4	4
118	Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 621-632.	3.1	13
119	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017, 18, 52.	1.8	34
120	Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2017, 5, e13140.	1.7	32
121	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease. <i>Journal of Hypertension</i> , 2017, 35, 1070-1078.	0.5	37
122	Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: a randomized open-label crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1479-1484.	4.4	67
123	Emerging drugs for the treatment of obesity. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 87-99.	2.4	29
124	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 734-738.	4.4	16
125	S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery. <i>Obesity Facts</i> , 2017, 10, 386-395.	3.4	17
126	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	2.3	6

#	ARTICLE	IF	CITATIONS
127	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. <i>Obesity Facts</i> , 2017, 10, 633-647.	3.4	23
128	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , 2017, 21, 1452-1460.	6.4	28
129	Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. <i>Diabetes Care</i> , 2017, 40, 132-135.	8.6	60
130	Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 153-155.	4.4	2
131	Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. <i>Diabetes Care</i> , 2017, 40, 117-124.	8.6	72
132	The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women. <i>Gynecological Endocrinology</i> , 2017, 33, 160-163.	1.7	28
133	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: <scp>A</scp> randomized, placebo-controlled, double-blind, parallel-group study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 773-782.	4.4	28
134	Semaglutide seems to be more effective the other GLP-1Ras. <i>Annals of Translational Medicine</i> , 2017, 5, 505-505.	1.7	31
135	Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. <i>Physiological Reports</i> , 2017, 5, e13073.	1.7	31
136	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. <i>Diabetes</i> , 2016, 65, 239-254.	0.6	41
137	Surgical or medical therapy for patients with obesity and T2DM?. <i>Nature Reviews Endocrinology</i> , 2016, 12, 500-502.	9.6	1
138	Retinal characteristics during 1Âyear of insulin pump therapy in type 1 diabetes: a prospective, controlled, observational study. <i>Acta Ophthalmologica</i> , 2016, 94, 540-547.	1.1	14
139	Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. <i>BMJ Open</i> , 2016, 6, e008377.	1.9	11
140	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. <i>Genome Medicine</i> , 2016, 8, 67.	8.2	260
141	Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. <i>BMJ Open</i> , 2016, 6, e008376.	1.9	30
142	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. <i>Molecular Systems Biology</i> , 2016, 12, 901.	7.2	188
143	Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2. <i>BMC Endocrine Disorders</i> , 2016, 16, 59.	2.2	11
144	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. <i>Cardiovascular Diabetology</i> , 2016, 15, 105.	6.8	48

#	ARTICLE	IF	CITATIONS
145	Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1236-1242.	1.2	59
146	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E505-E514.	3.5	56
147	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2016, 26, 2263-2267.	2.1	20
148	Relationship Between Two Common Lipoprotein Lipase Variants and the Metabolic Syndrome and Its Individual Components. <i>Metabolic Syndrome and Related Disorders</i> , 2016, 14, 442-448.	1.3	3
149	Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 317-332.	4.4	211
150	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. <i>Metabolomics</i> , 2016, 12, 1.	3.0	0
151	Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2016, , .	2.8	1
152	In vivo and in vitro degradation of peptide YY ₃₋₃₆ to inactive peptide YY ₃₋₃₄ in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R866-R874.	1.8	46
153	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 221-232.	11.4	127
154	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY ₃₋₃₆ . <i>European Journal of Endocrinology</i> , 2016, 174, 775-784.	3.7	72
155	Major rapid weight loss induces changes in cardiac repolarization. <i>Journal of Electrocardiology</i> , 2016, 49, 467-472.	0.9	12
156	Liraglutide for treating type 1 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 579-590.	3.1	15
157	Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 766-780.	11.4	74
158	Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 374-385.	2.3	54
159	Enhanced insulin signaling in human skeletal muscle and adipose tissue following gastric bypass surgery. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 309, R510-R524.	1.8	42
160	Postoperative Morbidity and Mortality in Type-2 Diabetics After Fast-Track Primary Total Hip and Knee Arthroplasty. <i>Anesthesia and Analgesia</i> , 2015, 120, 230-238.	2.2	62
161	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. <i>BMJ Open</i> , 2015, 5, e007791-e007791.	1.9	12
162	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E535-E544.	3.5	62

#	ARTICLE	IF	CITATIONS
163	Changes in Hematology and Calcium Metabolism After Gastric Bypass Surgery—a 2-Year Follow-Up Study. <i>Obesity Surgery</i> , 2015, 25, 1647-1652.	2.1	24
164	Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. <i>Diabetologia</i> , 2015, 58, 920-928.	6.3	27
165	Prenatal exposure to persistent organochlorine pollutants is associated with high insulin levels in 5-year-old girls. <i>Environmental Research</i> , 2015, 142, 407-413.	7.5	30
166	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2909-2917.	3.6	116
167	Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. <i>Diabetologia and Metabolic Syndrome</i> , 2015, 7, 12.	2.7	42
168	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E396-E406.	3.6	89
169	Updates in weight loss surgery and gastrointestinal peptides. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 21-28.	2.3	24
170	The Impact of Nocturnal Hypoglycemia on Sleep in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 2151-2157.	8.6	15
171	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. <i>Diabetes Care</i> , 2015, 38, 2250-2257.	8.6	91
172	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 600-607.	4.7	50
173	Bariatric Surgery - Effects on Obesity and Related co-Morbidities. <i>Current Diabetes Reviews</i> , 2014, 10, 208-214.	1.3	48
174	Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. <i>BMJ Open</i> , 2014, 4, e005942-e005942.	1.9	11
175	LY2605541—A Preferential Hepato-Specific Insulin Analogue. <i>Diabetes</i> , 2014, 63, 390-392.	0.6	20
176	GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery. <i>Diabetes</i> , 2014, 63, 3172-3174.	0.6	49
177	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. <i>Diabetes</i> , 2014, 63, 1725-1737.	0.6	220
178	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , 2014, 57, 1919-1926.	6.3	156
179	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , 2014, 7, 326.	1.4	1
180	Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 152-164.	11.4	248

#	ARTICLE	IF	CITATIONS
181	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. <i>Diabetologia</i> , 2013, 56, 2250-2254.	6.3	100
182	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. <i>Diabetologia</i> , 2013, 56, 2679-2687.	6.3	82
183	CRP and suPAR are differently related to anthropometry and subclinical organ damage. <i>International Journal of Cardiology</i> , 2013, 167, 781-785.	1.7	99
184	Under-reporting of adverse effects of tesofensine. <i>Lancet, The</i> , 2013, 382, 127.	13.7	9
185	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. <i>Obesity Research and Clinical Practice</i> , 2013, 7, e269-e274.	1.8	18
186	Treatment of the Metabolic Syndrome by Bariatric Surgery. , 2013, , 191-219.		0
187	Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance. <i>Diabetes</i> , 2013, 62, 2088-2094.	0.6	75
188	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1066-E1071.	3.6	66
189	Soluble urokinase plasminogen activator receptor, <sc>C</sc>â€reactive protein and triglyceride are associated with heart rate variability in nonâ€diabetic Danes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 457-468.	3.4	10
190	Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 1255-1264.	2.2	30
191	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved Î²-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 3044-3052.	0.6	262
192	Effects of Roux-en-Y Gastric Bypass on Fasting and Postprandial Levels of the Inflammatory Markers YKL-40 and MCP-1 in Patients with Type 2 Diabetes and Glucose Tolerant Subjects. <i>Journal of Obesity</i> , 2013, 2013, 1-10.	2.7	14
193	Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. <i>American Journal of Hypertension</i> , 2012, 25, 1095-1100.	2.0	11
194	Effects of Everyday Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusionâ€Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 210-217.	4.4	17
195	Type 2 diabetes: which drug as add-on to metformin?. <i>Lancet, The</i> , 2012, 379, 2222-2223.	13.7	2
196	Adipose expression of adipocytokines in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2012, 98, 235-241.	1.0	59
197	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. <i>European Journal of Internal Medicine</i> , 2012, 23, 132-136.	2.2	15
198	The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 410-419.	1.2	42

#	ARTICLE	IF	CITATIONS
199	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S251-S257.	8.6	233
200	Skeletal muscle mitochondrial function in polycystic ovarian syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 631-637.	3.7	23
201	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. <i>Diabetes</i> , 2011, 60, 2424-2433.	0.6	83
202	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β -Cell Function. <i>Diabetes</i> , 2011, 60, 1599-1607.	0.6	131
203	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β -Cell Function. <i>Diabetes Care</i> , 2011, 34, 1463-1468.	8.6	143
204	Studies of the Association of Arg72Pro of Tumor Suppressor Protein p53 with Type 2 Diabetes in a Combined Analysis of 55,521 Europeans. <i>PLoS ONE</i> , 2011, 6, e15813.	2.5	49
205	Sustained low-dose growth hormone therapy optimizes bioactive insulin-like growth factor level and may enhance CD4 T-cell number in HIV infection. <i>Journal of Medical Virology</i> , 2010, 82, 197-205.	5.0	3
206	Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion. <i>Diabetes Care</i> , 2010, 33, 375-377.	8.6	105
207	Studies of association between LPIN1 variants and common metabolic phenotypes among 17,538 Danes. <i>European Journal of Endocrinology</i> , 2010, 163, 81-87.	3.7	16
208	Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans. <i>Diabetes</i> , 2010, 59, 2160-2163.	0.6	126
209	On the role of glucose-dependent insulinotropic polypeptide in postprandial metabolism in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E614-E621.	3.5	64
210	Effect of Glucagon-Like Peptide-1 on β - and β -Cell Function in C-Peptide-Negative Type 1 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2492-2496.	3.6	45
211	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2367-2375.	3.6	31
212	The insulin-resistant phenotype of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2010, 94, 1052-1058.	1.0	31
213	Pancreatic β -cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2010, 160, 175-180.	1.9	6
214	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. <i>Regulatory Peptides</i> , 2010, 163, 96-101.	1.9	18
215	Relationship between common lipoprotein lipase gene sequence variants, hyperinsulinemia, and risk of ischemic heart disease: A population-based study. <i>Atherosclerosis</i> , 2010, 211, 506-511.	0.8	10
216	G-allele of Intronic rs10830963 in <i>MTNR1B</i> Confers Increased Risk of Impaired Fasting Glycemia and Type 2 Diabetes Through an Impaired Glucose-Stimulated Insulin Release. <i>Diabetes</i> , 2009, 58, 1450-1456.	0.6	125

#	ARTICLE	IF	CITATIONS
217	Incretin-Based Therapies. <i>Diabetes Care</i> , 2009, 32, S223-S231.	8.6	143
218	Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4679-4687.	3.6	89
219	Effect of Hyperglycemia on Mitochondrial Respiration in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1372-1378.	3.6	61
220	K _{ATP} Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 603-608.	3.6	48
221	Intramyocellular triglyceride content in man, influence of sex, obesity and glycaemic control. <i>European Journal of Endocrinology</i> , 2009, 161, 57-64.	3.7	13
222	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 463-477.	4.7	108
223	Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 586-593.	3.4	44
224	Reduced skeletal muscle mitochondrial respiration and improved glucose metabolism in nondiabetic obese women during a very low calorie dietary intervention leading to rapid weight loss. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1145-1152.	3.4	63
225	Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention. <i>Lipids in Health and Disease</i> , 2009, 8, 34.	3.0	10
226	Liraglutide Effect and Action in Diabetes (LEAD ₄) trial. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 119-129.	2.4	50
227	Treatment of type 2 diabetes with incretin-based therapies. <i>Lancet, The</i> , 2009, 373, 438-439.	13.7	31
228	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. <i>Current Diabetes Reviews</i> , 2009, 5, 266-275.	1.3	49
229	GLP-1: physiological effects and potential therapeutic applications. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 994-1003.	4.4	73
230	Glucagon-like peptide-1, glucose homeostasis and diabetes. <i>Trends in Molecular Medicine</i> , 2008, 14, 161-168.	6.7	152
231	Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 1906-1913.	13.7	173
232	C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 594-598.	2.8	40
233	Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. <i>Human Reproduction</i> , 2008, 23, 2113-2121.	0.9	80
234	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 491-499.	2.5	85

#	ARTICLE	IF	CITATIONS
235	Altered PI3-Kinase/Akt Signalling in Skeletal Muscle of Young Men with Low Birth Weight. <i>PLoS ONE</i> , 2008, 3, e3738.	2.5	76
236	Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1608-1610.	8.6	415
237	Altered Skeletal Muscle Fiber Composition and Size Precede Whole-Body Insulin Resistance in Young Men with Low Birth Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1530-1534.	3.6	122
238	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E324-E330.	3.5	92
239	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. <i>Regulatory Peptides</i> , 2007, 144, 123-130.	1.9	55
240	Studies of association of the CASQ1 rs2275703 polymorphism in relation to type 2 diabetes and related quantitative metabolic traits among 7088 Danish whites. <i>Molecular Genetics and Metabolism</i> , 2007, 92, 278-282.	1.1	2
241	Reduced Incretin Effect in Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1951-1959.	0.6	297
242	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2112-2119.	2.8	225
243	Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART. <i>Journal of Infection</i> , 2007, 54, 89-97.	3.3	6
244	Desaturation of Skeletal Muscle Structural and Depot Lipids in Obese Individuals during a Very-Low-Calorie Diet Intervention. <i>Obesity</i> , 2007, 15, 117-117.	3.0	20
245	Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution. <i>Clinical Endocrinology</i> , 2007, 67, 250-258.	2.4	7
246	Insulin and New Insulin Analogues with Focus on Type 2 Diabetes. , 2007, , 53-65.		2
247	Tumor necrosis factor α is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 175-182.	3.4	38
248	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. <i>Regulatory Peptides</i> , 2006, 137, 168-172.	1.9	52
249	Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity. <i>Clinical Endocrinology</i> , 2006, 64, 169-178.	2.4	67
250	β -cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. <i>Clinical Endocrinology</i> , 2006, 65, 554-554.	2.4	0
251	Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. <i>Journal of Infection</i> , 2006, 52, 389-398.	3.3	8
252	Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake. <i>European Journal of Endocrinology</i> , 2006, 155, 485-493.	3.7	168

#	ARTICLE	IF	CITATIONS
253	IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients. <i>Diabetes</i> , 2006, 55, 785-791.	0.6	47
254	beta-Cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. <i>Clinical Endocrinology</i> , 2005, 62, 354-361.	2.4	22
255	Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. <i>Journal of Medical Virology</i> , 2005, 77, 29-38.	5.0	36
256	Genetic and Nongenetic Regulation of CAPN10 mRNA Expression in Skeletal Muscle. <i>Diabetes</i> , 2005, 54, 3015-3020.	0.6	30
257	Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic β -cells. <i>European Journal of Endocrinology</i> , 2005, 152, 103-112.	3.7	32
258	Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4912-4919.	3.6	31
259	Altered Fat Tissue Distribution in Young Adult Men Who Had Low Birth Weight. <i>Diabetes Care</i> , 2005, 28, 151-153.	8.6	81
260	Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy. <i>Diabetes</i> , 2005, 54, 3474-3483.	0.6	29
261	In nondiabetic, human immunodeficiency virus-infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 171-179.	3.4	8
262	Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor γ 3 coactivator 1 α (PGC-1 α) gene in Danish subjects with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , 2005, 67, 175-179.	2.8	38
263	Young, low-birth-weight men are not more susceptible to the diabetogenic effects of a prolonged free fatty acid exposure than matched controls. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1398-1406.	3.4	3
264	Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of β -cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E677-E685.	3.5	23
265	Dissociation between Fat-Induced Insulin Resistance and Proximal Insulin Signaling in Skeletal Muscle in Men at Risk for Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1301-1311.	3.6	52
266	Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1910-1914.	8.6	35
267	Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 832-839.	1.5	17
268	Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211). <i>Diabetes Care</i> , 2004, 27, 1335-1342.	8.6	296
269	Angiotensin-Receptor Blockade versus Converting Enzyme Inhibition in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2004, 351, 1952-1961.	27.0	844
270	Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic Human Immunodeficiency Virus-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1565-1573.	3.4	12

#	ARTICLE	IF	CITATIONS
271	Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 885-894.	3.4	55
272	Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β -cell function. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1343-1353.	3.4	48
273	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. <i>Regulatory Peptides</i> , 2003, 114, 115-121.	1.9	360
274	The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on β -Cell Sensitivity in Type 2 and Nondiabetic Subjects. <i>Diabetes</i> , 2003, 52, 380-386.	0.6	513
275	Increased expression of TNF- α , IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E1072-E1080.	3.5	165
276	Insulin Secretion and Cellular Glucose Metabolism after Prolonged Low-Grade Intralipid Infusion in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2775-2783.	3.6	39
277	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. <i>Diabetes Care</i> , 2003, 26, 2581-2587.	8.6	39
278	Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 883-888.	8.6	125
279	Studies of the Pro12Ala Polymorphism of the PPAR- γ Gene in the Danish MONICA Cohort: Homozygosity of the Ala Allele Confers a Decreased Risk of the Insulin Resistance Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3989-3992.	3.6	112
280	Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight. <i>Diabetes</i> , 2002, 51, 1271-1280.	0.6	172
281	Sulfatide Controls Insulin Secretion by Modulation of ATP-sensitive K ⁺ -Channel Activity and Ca ²⁺ -Dependent Exocytosis in Rat Pancreatic β -Cells. <i>Diabetes</i> , 2002, 51, 2514-2521.	0.6	46
282	Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β -cell function in type 2 diabetes: a parallel-group study. <i>Lancet</i> , The, 2002, 359, 824-830.	13.7	1,207
283	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3717-3723.	3.6	767
284	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3717-3723.	3.6	224
285	Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. <i>Contraception</i> , 1999, 60, 337-344.	1.5	23
286	Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 274, E716-E725.	3.5	9
287	Sham Feeding Increases Glucose Tolerance by a Mechanism Independent of Insulin Secretion in Normal Subjects. <i>Digestion</i> , 1995, 56, 253-258.	2.3	9
288	Clinical evaluation of a prototype glucose electrode. <i>Biosensors and Bioelectronics</i> , 1992, 7, 683-687.	10.1	2

#	ARTICLE	IF	CITATIONS
289	A rapid method for determination of human C-peptide in plasma. <i>Clinica Chimica Acta</i> , 1991, 196, 1-6.	1.1	2
290	Gastric Inhibitory Polypeptide in Newly Diagnosed Ketotic Type I (Insulinâ€dependent) Diabetics. <i>Acta Medica Scandinavica</i> , 1988, 223, 437-441.	0.0	7
291	Metabolic and Cardiovascular Responses to Epinephrine in Diabetic Autonomic Neuropathy. <i>New England Journal of Medicine</i> , 1987, 317, 421-426.	27.0	66
292	Heterogeneity of immunoreactive gastric inhibitory polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. <i>European Journal of Endocrinology</i> , 1987, 114, 74-83.	3.7	6
293	Effect of porcine gastric inhibitory polypeptide on Î²-cell function in type I and type II diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 677-682.	3.4	107
294	Rapid changes in plasma androgens during insulin withdrawal in male Type 1 (insulin-dependent) diabetics. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 21-25.	3.3	6
295	The importance of plasma free insulin and counterregulatory hormones for the recovery of blood glucose following hypoglycaemia in Type 1 diabetics. <i>European Journal of Endocrinology</i> , 1985, 108, 224-230.	3.7	14
296	Relation of immunoreactive gastric inhibitory polypeptide to changes in glycaemic control and B cell function in Type 1 (insulin-dependent) diabetes mellitus. <i>European Journal of Endocrinology</i> , 1984, 105, 221-225.	3.7	5
297	Factors of Importance for Residual Betaâ€cell Function in Type I Diabetes Mellitus. <i>Acta Medica Scandinavica</i> , 1983, 213, 61-67.	0.0	8
298	Whole Body Clearance of Norepinephrine. THE SIGNIFICANCE OF ARTERIAL SAMPLING AND OF SURGICAL STRESS. <i>Journal of Clinical Investigation</i> , 1983, 71, 500-505.	8.2	61
299	Plasma testosterone and androstenedione in insulin dependent patients at time of diagnosis and during the first year of insulin treatment. <i>European Journal of Endocrinology</i> , 1982, 100, 406-409.	3.7	23
300	No Response of Pancreatic Hormones to Hypoglycemia in Diabetic Autonomic Neuropathy*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1982, 54, 815-819.	3.6	49
301	Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. <i>Clinica Chimica Acta</i> , 1982, 120, 243-250.	1.1	36
302	Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. <i>European Journal of Clinical Investigation</i> , 1982, 12, 81-85.	3.4	167
303	Decreased Insulin Removal Contributes to Hyperinsulinemia in Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981, 53, 618-621.	3.6	170
304	Practical Clinical Value of the Câ€Peptide Response to Glucagon Stimulation in the Choice of Treatment in Diabetes Mellitus. <i>Acta Medica Scandinavica</i> , 1981, 210, 153-156.	0.0	154
305	Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. <i>European Journal of Endocrinology</i> , 1980, 95, 359-363.	3.7	43